REG - IP Group PLC - AGM Statement

IPAnnouncement

14/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220614:nRSN7253Oa&default-theme=true

RNS Number : 7253O  IP Group PLC  14 June 2022

 FOR RELEASE ON  14 June 2022

 

IP Group plc - AGM statement

 

IP Group plc (LSE: IPO) ("IP Group" or "the Company" or "the Group"),
which develops world-changing science and technology businesses across life
sciences, technology and cleantech, issues the following statement ahead of
its Investor Update event and Annual General Meeting ("AGM") taking place this
morning.

 

This statement provides an update on the Group's progress for the period since
31 December 2021. No material new information will be released by the Company
during the event or AGM. The Group anticipates releasing its results for the
six months to 30 June in early August.

 

Business and operational update

IP Group remains well financed and, as at 31 May 2021, had gross cash and
deposits of £251 million (FY21: £322 million), having deployed £45.9m of
capital in the year to date. The Group has made notable investments into
existing portfolio companies Istesso Ltd (£10m) and Bramble Ltd (£9.5m) as
well as a number of smaller size investments into current and new
opportunities across all three of our thematic focus areas of life sciences,
cleantech and deeptech.

 

As at 31 May, the Group's Net Asset Value was approximately £1,436m, or 139
pence per share, compared with £1,738m, or 167pps, at 31 December 2021. The
fall in value in the year to date is largely attributable to the reduction in
value of the Group's public portfolio which has been impacted by the
correction in global stock markets, particularly by the rotation out of growth
and technology stocks.

 

IP Group's public portfolio recorded a fair value reduction of £360m in the
period to 31 May 2022, of which £309m related to the fall in the share price
of Oxford Nanopore. Technologies plc. In the private portfolio, the Group has
seen fair value gains of over £60m, the majority of which is attributable to
an initial uplift in the fair value of portfolio company First Light Fusion
Ltd after it confirmed it had achieved fusion in April. There has been no
significant impact on private portfolio funding rounds to date.

 

The Group continues to believe that the prospects for our portfolio are strong
and the scale of the opportunity remains significant and is therefore
focussing on its leading assets while planning for reduced realisations given
the current market backdrop.

 

Shareholder returns

The Board remains focussed on shareholder value creation, having introduced a
share buyback programme and dividends.

During 2021, the Group paid its maiden dividend, a final 2020 dividend of 1
pence per share, in June 2021. Additionally, the Group paid an interim
dividend of 0.48 pence per share in September 2021. A final 2021 dividend of
0.72 pence per share has been proposed, with the Directors offering
shareholders the opportunity to elect to receive dividends in the form of
fully paid shares in IP Group plc in lieu of cash under the Scrip Dividend
Scheme. Subject to its approval at the 2022 AGM later today, this will be paid
on 30 June 2022 to shareholders on the register on 27 May 2022.

 

The Board continues to consider that shareholder returns will be driven
primarily by long-term capital appreciation. The Board remains committed to
delivering a regular dividend income, which is intended to comprise a
relatively small component of total shareholder return. We will also continue
to consider share buyback programmes and other capital return tools as we
generate realisations from our portfolio.

 

The Board will seek shareholder approval to renew the authority to purchase up
to 10% of the Ordinary Shares in issue from the date of grant of the authority
to the date of the Annual General Meeting in 2023. Such purchases will only be
made at a discount to the prevailing NAV per share. Any such shares that are
bought back may be held in treasury and may subsequently then either be sold
for cash or cancelled.

 

Portfolio update

The Group's portfolio includes holdings in 49 'focus' companies across life
sciences, deeptech and cleantech, representing over 80% of the portfolio value
of £1.3bn at 31 May 2022.

Significant developments in the Group's portfolio since 31 December 2021
include:

·    First Light Fusion Ltd, which is researching energy generation via
inertial fusion, completed its Series C fund raise in February, raising
c.£33m from both existing and new investors. IP Group committed £5m to the
funding round and, following completion, has an undiluted beneficial holding
of 27.4%. IP Group has recorded a net unrealised fair value gain of £27.2m
or 3p per share. In April, First Light confirmed that it had achieved fusion,
independently validated by the UK Atomic Energy Authority (UKAEA). IP Group
believes achieving this world-first will at least result in an initial
doubling of the value of the Company with recent comparatives and third-party
valuation work suggesting a doubling to quadrupling may be achieved at the
next funding round. Our preliminary assessment, based upon the lower end of
the range, implies a carrying value of the asset that will generate an initial
net fair value gain of at least £57m (or approximately 5 pence per share). As
at 31 December 2021, IP Group's undiluted beneficial holding of 27.4% in
First Light was valued at £57.3m.

·    IP Group and Parkwalk co-led an £8.4m Series A round into GripAble
Ltd, a digital healthcare start-up delivering rehabilitation programmes to
people with neurological and musculoskeletal conditions. IP Group committed
£3.5m to the funding round and, following completion, has an undiluted
beneficial holding of 25.4% in GripAble. Parkwalk, IP Group's wholly owned EIS
fund manager, also committed £3.5m to the round.

·   Microbiotica Ltd, a leading player in discovering and developing
microbiome-based therapeutics and biomarkers, completed a £50m Series B
financing round, the largest microbiome-related financing in Europe to date.
IP Group committed £4m to the funding round and, following completion, has
an undiluted beneficial holding of 18.2% in Microbiotica, valued at
£16.1m. IP Group recorded a net unrealised fair value gain of £2.2m.

·    Bramble Energy Ltd, a London-based fuel cell company, completed a
£35m Series B investment round. IP Group committed approximately £10m to the
round and, following completion, has an undiluted beneficial holding of 32.3%
in Bramble, valued at £20.7m, representing a net unrealised fair value gain
to the Group of approximately £6.6m.

 

This announcement may contain forward looking statements. These statements
reflect the Board's current view, are subject to a number of material risks
and uncertainties and could change in the future. Factors which could cause or
contribute to such changes include, but are not limited to, the general
economic climate and market conditions, as well as specific factors relating
to the financial or commercial prospects or performance of individual
companies within the Group's portfolio.

 

For more information, please contact:

 

 IP Group plc                                             www.ipgroupplc.com (http://www.ipgroupplc.com)
 Liz Vaughan-Adams, Communications                        +44 (0) 20 7444 0050

+44 (0) 20 7444 0062/+44 (0) 7967 312125
 Charlotte Street Partners
 David Gaffney                                            +44 (0) 7854 609998
 Andrew Wilson                                            +44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across life
sciences, technology and cleantech. The Group has a strong track record of
success, having been the founder investor in a number of high-profile
companies including Oxford Nanopore Technologies plc, and has one of the most
exciting portfolios of high-growth businesses in Europe. The Group also owns
Parkwalk, the UK's largest growth EIS fund manager which backs world-changing
technologies emerging from the UK's leading universities and research
institutions. IP Group is listed on the Main Market of the London Stock
Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMFXLLFLQLFBBB